Improving Lives Through

Innovative Diagnostic Solutions

AXIM is an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics solutions

Improving Lives Through

Innovative Diagnostic Solutions

AXIM is an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics solutions

COVID-19 TESTING

AXIM Biotech has developed a rapid (10-minute) serological diagnostic test that detects SARS-CoV-2 neutralizing antibodies (Nabs) which are the antibodies needed to fight COVID-19 within the body.

AXIM EYE

AXIM looks to assist doctors in diagnosing dry eye disease (DED) faster and more efficiently than alternative methods.  

CANCER dIAGNOSTICS

AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer

The Latest On Our Research

Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing the landscape of diagnosis of SARS-CoV-2 (COVID-19), dry eye disease (DED) and Oncological indications. AXIM’s COVID-19 neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and ophthalmological conditions such as DED.